Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country

Hikmat Abdel-Razeq,1,2 Baha Sharaf,1 Suhaib Khater,1 Huda Jafar Baidoun,2 Hira Bani Hani,1 Ayat Taqash,3 Osama El Khatib,1 Sarah Edaily,1 Mahmoud Abunasser,1 Faris Tamimi,1 Yosra Nabeel Al-Masri,1 Tamer Moh’d Waleed Al-Batsh,1 Anas Zayed,1 Tala Ghatasheh,1 Tala Radaideh1 1Department of Internal Medi...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	ImmunoTargets and Therapy
المؤلفون الرئيسيون:	Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Dove Medical Press 2024-09-01
الموضوعات:	metastatic breast cancer mbc cdk4/6 inhibitors ribociclib aromatase inhibitors fulvestrant
الوصول للمادة أونلاين:	https://www.dovepress.com/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-peer-reviewed-fulltext-article-ITT

مواد مشابهة

A retrospective study of 500 mg fulvestrant in recurrent or metastatic breast cancer patients pretreated with the third generation of aromatase inhibitors
حسب: 赵燕南, وآخرون
منشور في: (2016-10-01)

Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer
حسب: Tugay Avci, وآخرون
منشور في: (2025-03-01)

Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution
حسب: Maria Inês Teodoro, وآخرون
منشور في: (2024-12-01)

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
حسب: Al-Batsh T, وآخرون
منشور في: (2025-03-01)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
حسب: Xing Huang
منشور في: (2019-11-01)

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer
حسب: Mahtani RL, وآخرون
منشور في: (2019-01-01)

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance
حسب: Costanza Paoletti, وآخرون
منشور في: (2016-08-01)

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer
حسب: Baha’ Sharaf, وآخرون
منشور في: (2024-05-01)

Aromatase inhibitors in the treatment of endometriosis
حسب: Radosław Słopień, وآخرون
منشور في: (2016-03-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
حسب: Lu Turković, وآخرون
منشور في: (2022-05-01)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
حسب: P. Neven, وآخرون
منشور في: (2023-08-01)

Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
حسب: Fulvio Borella, وآخرون
منشور في: (2023-08-01)

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
حسب: Abhira Deb, وآخرون
منشور في: (2025-01-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
حسب: Colombo GL, وآخرون
منشور في: (2023-03-01)

Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer
حسب: Snehal Aditya Arvindekar, وآخرون
منشور في: (2024-09-01)

Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review
حسب: Maissoune Hajir, وآخرون
منشور في: (2023-09-01)

Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer
حسب: Senthil Rajappa, وآخرون
منشور في: (2018-01-01)

Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature
حسب: Bhavika Kothari, وآخرون

Effect of Aromatase Inhibitor ,Sage And Flaxseed on Spermatogenesis In Rat
حسب: Heba jasem, وآخرون
منشور في: (2020-03-01)

The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy
حسب: Nahid Punjani, MD, MPH, وآخرون
منشور في: (2021-08-01)

Update in the clinical utilization of chemoprevention for breast cancer: a narrative review
حسب: Razan Mansour, وآخرون
منشور في: (2025-06-01)

Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target
حسب: Jessica Caciolla, وآخرون
منشور في: (2020-11-01)

Aromatase inhibitors in the treatment of deep endometriosis
حسب: Simone Ferrero, وآخرون
منشور في: (2009-09-01)

Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy
حسب: Andi Tian, وآخرون
منشور في: (2025-01-01)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
حسب: Hatice Odabas, وآخرون
منشور في: (2023-03-01)

Sex reversed chicks (Gallus domesticus) hatched from eggs treated with aromatase inhibitor YM511
حسب: P. Trefil, وآخرون
منشور في: (2004-12-01)

Study on the effect of aromatase inhibitors and antiestrogens on the sex differentiation of broiler chicks
حسب: E.A Valizadeh, وآخرون
منشور في: (2011-02-01)

Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
حسب: Tan Y, وآخرون
منشور في: (2026-06-01)

Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
حسب: Nicholas A. Young, وآخرون
منشور في: (2022-12-01)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
حسب: Cengiz Karacin, وآخرون
منشور في: (2023-02-01)

Origin of aromatase inhibitory activity via proteochemometric modeling
حسب: Saw Simeon, وآخرون
منشور في: (2016-05-01)

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study
حسب: Ahmet Oruç, وآخرون
منشور في: (2026-03-01)

Ribociclib in newly diagnosed hepatitis B infection: A case report
حسب: Fabrizio Di Costanzo, وآخرون
منشور في: (2023-06-01)

Ribociclib-induced phototoxicity - the era of new drugs and new toxicities
حسب: Bobić Simonida, وآخرون
منشور في: (2024-01-01)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
حسب: Wonjin Kim, وآخرون
منشور في: (2015-03-01)

Ribociclib in patient with hormone-positive HER2-negative breast cancer with brain metastases: a case report
حسب: N. S. Prizova, وآخرون
منشور في: (2022-06-01)

Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies
حسب: Bobo JA, وآخرون
منشور في: (2025-04-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
حسب: Zvonimir Mlinarić, وآخرون
منشور في: (2022-11-01)

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation
حسب: Jyun-Yan Jhan, وآخرون
منشور في: (2023-08-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
حسب: I. P. Ganshina, وآخرون
منشور في: (2019-06-01)